• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Augmentin (amoxicillin/clavulanate)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Augmentin (amoxicillin/clavulanate)

  • Profile

Profile

Contact Information

Currently Enrolling Trials

    Show More

    General Information

    A new adult dosing regimen of Augmentin has been approved. Augmentin is an antibiotic used to treat various respiratory-tract infections, including sinusitis, bronchitis, and pneumonia.

    In the new regimen, Augmentin is administered twice a day (BID), every 12 hours, in contrast to three-times-a-day regimen used since Augmentin was introduced in the United States.

    The BID regimen for more severe infections and infections of the respiratory tract consists of a new tablet containing 875 mg of amoxicillin and 125 mg of clavulanate potassium. In addition, the currently marketed tablet containing 500 mg of amoxicillin and 125 mg of clavulanate potassium can now be prescribed on a twice-a-day regimen for less severe infections that may be treated with a lower dose.

    Augmentin should not be used in subjects with a history of allergic reactions to any penicillin or with a previous history of Augmentin-associated cholestatic jaundice/hepatic dysfunction.

    Side Effects

    The side effects of Augmentin, which are primarily mild and self-limiting, include diarrhea and nausea. In adult subjects treated for more severe infections during clinical trials, there was a 60% reduction in the number of subjects experiencing severe diarrhea or withdrawing from trials because of diarrhea.

    Approval Date: 1996-02-01
    Company Name: SmithKline Beecham
    Back to Listings

    Upcoming Events

    • 26Jan

      Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

    • 27Jan

      Medical Device Clinical Trials in China: Latest Regulatory Developments

    • 11Feb

      Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

    • 23Mar

      Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

    • 26Apr

      MAGI's Clinical Research vConference — Spring 2021

    Featured Products

    • Regenerative Medicine – Steps to Accelerate Development : PDF

      Regenerative Medicine: Steps to Accelerate Development

    • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

      Clinical Trial Agreements: A Guide to Key Words and Phrases

    Featured Stories

    • Virtual Doctoer

      Simple Changes Can Make Trials More Patient Friendly

    • Drug approval

      Two-Thirds of Trial Subjects for Drug Approvals Are Outside the U.S.

    • VaccinewithNeedle-360x240.png

      Rules of Vaccine Approval May Be Changing, But Statistical Analysis Tools Remain Constant

    • AskTheExperts-360x240.png

      Ask the Experts: Trial Operations Adjustments in a Remote World

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell My Personal Information

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing